Do we use all the options of topical therapy for upper respiratory tract inflammatory conditions? A review

封面

如何引用文章

全文:

详细

Anti-infectious immunity is a combination of mechanisms and responses that the body uses to resist external pathogens. The article describes the protective properties of one of these external barriers, the respiratory tract (RT) mucosa, as well as the factors affecting it and ways to correct the consequences of adverse effects. Methods for preventing or reducing the number of seasonal respiratory diseases and reducing the impact of adverse environmental factors are described, and data on the effect of topical drugs on the functional state of the RT epithelium and mucosa in the context of choosing the most "safe" drug without loss of clinical efficacy are presented. New data on the antiviral and anti-inflammatory activity of Euphorbium Compositum® Nasentropfen s nasal spray show that this topical agent helps to maintain the integrity of the epithelial barrier and improves the overall immunological and barrier functions of the RT ciliated epithelium and mucosa.

全文:

受限制的访问

作者简介

Elena Radtsig

Pirogov Russian National Research Medical University (Pirogov University)

编辑信件的主要联系方式.
Email: radsig_e@rsmu.ru
ORCID iD: 0000-0003-4613-922X

D. Sci. (Med.), Prof.

俄罗斯联邦, Moscow

Maria Kulmakova

Pirogov Russian National Research Medical University (Pirogov University)

Email: radsig_e@rsmu.ru
ORCID iD: 0000-0002-5090-9269

Graduate Student

俄罗斯联邦, Moscow

参考

  1. Заболеваемость населения по основным классам болезней. Федеральная служба государственной статистики. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdr2-1.xls. Ссылка активна на 04.02.2025 [Zabolevaemost' naseleniia po osnovnym klassam boleznei. Federal'naia sluzhba gosudarstvennoi statistiki. Available at: https://rosstat.gov.ru/storage/mediabank/Zdr2-1.xls. Accessed: 04.02.2025 (in Russian)].
  2. Острая респираторная вирусная инфекция (ОРВИ). Клинические рекомендации. 2022. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/25_2. Ссылка активна на 04.02.2025 [Ostraia respiratornaia virusnaia infektsiia (ORVI). Klinicheskie rekomendatsii. 2022. Available at: https://cr.minzdrav.gov.ru/preview-cr/25_2. Accessed: 04.02.2025 (in Russian)].
  3. Азнабаева Л.Ф. Иммунологические аспекты воспаления верхних дыхательных путей. Вестник оториноларингологии. 2012;77(6):23-6 [Aznabaeva LF. Immunological aspects of inflammation of the upper respiratory tract. Russian Bulletin of Otorhinolaryngology. 2012;77(6):23-6 (in Russian)].
  4. Радциг Е.Ю., Радциг А.Н., Варавина М.А. Защитные свойства и способы активации слизистых оболочек верхних дыхательных путей. Российский вестник перинатологии и педиатрии. 2021;66(1):140-6 [Radtsig EYu, Radtsig AN, Varavina MA. Protective properties of the mucosa of the upper respiratory tract and methods of their activation. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(1):140-6 (in Russian)]. doi: 10.21508/1027-4065-2021-66-1-140-146
  5. Kudo E, Song E, Yockey LJ, et al. Low ambient humidity impairs barrier function and innate resistance against influenza infection. Proc Natl Acad Sci U S A. 2019;116(22):10905-10. doi: 10.1073/pnas.1902840116
  6. Matsumoto S, Ishii R, Kiuchi C, et al. Effect of Average Relative Humidity on Epistaxis. Cureus. 2023;15(3):e36063. doi: 10.7759/cureus.36063
  7. Yonghua S, Mehrabi Nasab E, Liuo Y. Effect of Temperature and Humidity on the Allegro-inflammatory Factors and Allergic Rhinitis-related Behavior. Iran J Allergy Asthma Immunol. 2022;21(6):704-10. doi: 10.18502/ijaai.v21i6.11531
  8. Akdag M, Bakir S, Alabalik U, et al. Does usage of a room air freshener affect the nasal mucosa? Am J Rhinol Allergy. 2014;28(6):202-8. doi: 10.2500/ajra.2014.28.4105
  9. Huang D, Taha MS, Nocera AL, et al. Cold exposure impairs extracellular vesicle swarm-mediated nasal antiviral immunity. J Allergy Clin Immunol. 2023;151(2):509-25.e8. doi: 10.1016/j.jaci.2022.09.037
  10. McGrath JJC, Thayaparan D, Cass SP, et al. Cigarette smoke exposure attenuates the induction of antigen-specific IgA in the murine upper respiratory tract. Mucosal Immunol. 2021;14(5):1067-76. doi: 10.1038/s41385-021-00411-9
  11. Rebuli ME, Glista-Baker E, Hoffman JR, et al. Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial. Am J Respir Cell Mol Biol. 2021;64(1):126-37. doi: 10.1165/rcmb.2020-0164OC
  12. Graf P. Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. Clin Ther. 1999;21(10):1749-55. doi: 10.1016/S0149-2918(99)80053-8
  13. Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology. 1996;34(1):9-13.
  14. Graf P, Hallén H. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment. ORL J Otorhinolaryngol Relat Spec. 1997;59(1):39-44. doi: 10.1159/000276903
  15. Graf P, Juto JE. Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling. Rhinology. 1995;33(1):14-7.
  16. Russo E, Giombi F, Paoletti G, et al. Use, Abuse, and Misuse of Nasal Medications: Real-Life Survey on Community Pharmacist's Perceptions. J Pers Med. 2023;13(4):579. doi: 10.3390/jpm13040579
  17. Радциг А.Н. Выбор топического деконгестанта для симптоматической терапии назальной обструкции. Фарматека. 2021;28(1):115-8 [Radtsig AN. Choice of topical decongestant for symptomatic treatment of nasal obstruction. Farmateka. 2021;28(1):115-8 (in Russian)]. doi: 10.18565/pharmateca.2021.1.115-118
  18. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-67. doi: 10.1016/j.jaci.2020.07.007
  19. Siddiqui ZA, Walker A, Pirwani MM, et al. Allergic rhinitis: diagnosis and management. Br J Hosp Med (Lond). 2022;83(2):1-9. doi: 10.12968/hmed.2021.0570
  20. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. International Forum of Allergy & Rhinology. 2023;13(4):293-859. doi: 10.1002/alr.23090
  21. Rajput C, Ganjian H, Muruganandam G, et al. Euphorbium compositum SN improves the innate defenses of the airway mucosal barrier network during rhinovirus infection. Respir Res. 2024;25(1):407. doi: 10.1186/s12931-024-03030-7
  22. Glatthaar-Saalmüller B, Fallier-Becker P. Antiviral action of Euphorbium compositum and its components. Forsch Komplementarmed Klass Naturheilkd. 2001;8(4):207-12. doi: 10.1159/000057223
  23. Ammerschläger H, Klein P, Weiser M, Oberbaum M. Treatment of inflammatory diseases of the upper respiratory tract – comparison of a homeopathic complex remedy with xylometazoline. Forsch Komplementarmed Klass Naturheilkd. 2005;12(1):24-31 (in German). doi: 10.1159/000082934
  24. Weiser M, Clasen BPE. Randomized, placebo-controlled double-blind study to investigate the clinical efficacy of the homeopathic medication Euphorbium compositum Nasal Spray S in chronic sinusitis. Forsch Komplementarmed Klass Naturheilkd. 1994;13(1):251-9 (in German).
  25. Zenner S, Metelmann H. Empirical data on therapy with a homeopathic nasal spray. Biomed Ther. 1997;15(3):82-8.
  26. Raab V. Further therapy experience with Euphorbium compositum nasal drops (metered-dose spray without propellant gas) in the ENT specialist practice. Biologische Medizin. 1982;11(4):176-9 (in German).
  27. Connert WD, Maiwald J. The therapy of rhinopathy: results of application of a biotherapeutic nasal spray. Biol Ther. 1991;9(4):182-92.
  28. Urlea-Schön I, Corgiolu M. Effectiveness and tolerability of Euphorbium compositum SN for the symptomatic treatment of rhinitis in children aged 2–6 years. Eur J Integr Med. 2009;1(4):236 (Abstract PO-023).
  29. Горелов А.В., Зайцева О.В., Геппе Н.А., и др. Резолюция Совета экспертов. Патогенетическая, симптоматическая и саногенетическая терапия острых респираторных инфекций. Вопросы практической педиатрии. 2023;18(5):95-9 [Gorelov AV, Zaytseva OV, Geppe NA, et al. Resolution of the Council of Experts. Pathogenetic, symptomatic and sanogenetic therapy of acute respiratory infections. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2023;18(5):95-9 (in Russian)]. doi: 10.20953/1817-7646-2023-5-95-99

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Ciliated epithelium.

下载 (153KB)
3. Fig. 2. Mucociliary clearance system.

下载 (147KB)
4. Fig. 3. Synthesis of secretory IgA in the submucosa and transepithelial transport in the respiratory tract.

下载 (351KB)
5. Fig. 4. Destruction and disorganization of the ciliated epithelium during inflammation.

下载 (273KB)

版权所有 © Consilium Medicum, 2025

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.